Table 1.
Technical and sampling details of the relevant studies about the possible role of the telomere length in COVID-19 pathogenies.
| Aim of study | Sample Type | Sample Size | Method(s) | Reference |
|---|---|---|---|---|
| Analysis of association between telomere length and lymphocyte count in COVID-19 patients | Peripheral Blood | 17 COVID-19 patients, 21 non-COVID-19 patients |
TeSLA, SB |
(Benetos et al., 2021) |
| Age-Dependent Assessment of gene expression in crucial pathways of cellular maintenance |
Lung Tissue | 48 patients/controls * | qPCR | (Maremanda et al., 2020) |
| Analysis of association between telomere length and the risk of severe COVID-19 | Peripheral Blood | 70 COVID-19 patients , 491 control |
Flow-FISH | (Froidure et al., 2020) |
| Analysis of association between telomere length and COVID-19 severity | Peripheral Blood | 89 COVID-19 patients | qPCR | (Sanchez-Vazquez et al., 2021) |
| Investigation of biological risk for Pulmonary fibrosis in COVID-19 survivors | Peripheral Blood | 76 COVID-19 survivors | qPCR | (McGroder et al., 2021) |
TeSLA, Telomere Shortest Length Assay; SB, Southern Blotting; qPCR, quantitative Polymerase Chain Reaction, FISH, Fluorescent In Situ Hybridization.
*Including non-smokers, smokers, and patients with COPD and IPF.